Episealer®: Presentation from ESSKA 2021 available online
Episurf Medical (Nasdaq: EPIS B) today announces that the presentation "Episealer mini metal implant in the Knee and Ankle” by Associate Professor Tim Spalding from University Hospitals Coventry and Warwickshire NHS Trust, UK, and Professor Niek van Dijk from the FIFA Medical Center of Excellence, Madrid, Spain, which was presented at the 19th ESSKA congress during the previous week, will be made available today, Monday May 17th, on Episurf Medical’s website (www.episurf.com/healthcare-professionals/scientific-presentations). The presentation covers Episurf Medical’s technology for both the knee and the ankle.
The presentation about the Episealer® Knee implant focuses on clinical results from the European multicentre study with 24 months’ follow-up of 80 Episealer® Knee implant patients (“Patient specific metal implants for focal chondral and osteochondral lesions in the knee – Excellent clinical results at 2 years”) previously published in KSSTA by Dr. med. Johannes Holz, Park-Klinik Manhagen, OrthoCentrum, Hamburg, Germany et al. The presentation about the Episealer® Talus technology focuses on surgical technique and early experiences from the use of the recently launched ankle implant Episealer® Talus.
“The annual ESSKA congress is a very important scientific congress, gathering surgeons and industry participants from all over the world. Hence, it is a great milestone for us to have the Episealer® technology presented by two world renowned orthopedic surgeons,” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: